CRISPR Therapeutics AG

117.26+0.9600+0.83%Vol 765.81K1Y Perf 38.11%
Sep 15th, 2021 16:00 DELAYED
BID116.05 ASK117.26
Open116.21 Previous Close116.30
Pre-Market- After-Market-
 - -%  - -
Target Price
163.60 
Analyst Rating
Moderate Buy 2.09
Potential %
39.52 
Finscreener Ranking
★★★★★     62.37
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★★     63.86
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     85.15
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
26.94 
Earnings Rating
Strong Sell
Market Cap8.94B 
Earnings Date
27th Oct 2021
Alpha0.02 Standard Deviation0.21
Beta2.23 

Today's Price Range

114.42117.34

52W Range

79.31220.20

5 Year PE Ratio Range

-13.00185.10

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-3.46%
1 Month
-4.32%
3 Months
-5.37%
6 Months
-10.19%
1 Year
38.11%
3 Years
111.81%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CRSP117.260.96000.83
AAPL149.030.91000.61
GOOG2 904.1236.00001.26
MSFT304.825.03001.68
XOM56.421.84003.37
WFC46.640.59001.28
JNJ165.420.62000.38
FB373.92-2.6100-0.69
GE102.161.78001.77
JPM158.161.09000.69
Financial StrengthValueIndustryS&P 500US Markets
25.90
26.20
0.06
0.07
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
49.70
50.90
-10 850.20
50.71
RevenueValueIndustryS&P 500US Markets
901.76M
11.83
33.20
49.12
Earnings HistoryEstimateReportedSurprise %
Q02 20214.199.44125.30
Q01 2021-1.45-1.51-4.14
Q04 2020-1.23-1.50-21.95
Q03 2020-1.17-1.32-12.82
Q02 2020-0.92-1.30-41.30
Q01 2020-1.09-1.15-5.50
Q04 20190.040.511.18K
Q03 2019-0.952.40352.63
Earnings Per EndEstimateRevision %Trend
9/2021 QR-1.68-342.11Negative
12/2021 QR-1.71-13.25Negative
12/2021 FY4.81628.79Positive
12/2022 FY-7.24-16.21Negative
Next Report Date27th Oct 2021
Estimated EPS Next Report-1.68
Estimates Count9
EPS Growth Next 5 Years %-
Volume Overview
Volume765.81K
Shares Outstanding76.20M
Shares Float52.41M
Trades Count17.05K
Dollar Volume283.98M
Avg. Volume1.65M
Avg. Weekly Volume834.06K
Avg. Monthly Volume846.07K
Avg. Quarterly Volume1.24M

CRISPR Therapeutics AG (NASDAQ: CRSP) stock closed at 117.26 per share at the end of the most recent trading day (a 0.83% change compared to the prior day closing price) with a volume of 773.54K shares and market capitalization of 8.94B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 410 people. CRISPR Therapeutics AG CEO is Samarth Kulkarni.

The one-year performance of CRISPR Therapeutics AG stock is 38.11%, while year-to-date (YTD) performance is -23.41%. CRSP stock has a five-year performance of %. Its 52-week range is between 79.31 and 220.2, which gives CRSP stock a 52-week price range ratio of 26.94%

CRISPR Therapeutics AG currently has a PE ratio of 23.70, a price-to-book (PB) ratio of 3.53, a price-to-sale (PS) ratio of 9.97, a price to cashflow ratio of 16.60, a PEG ratio of 2.32, a ROA of 22.31%, a ROC of 23.78% and a ROE of 25.06%. The company’s profit margin is 50.71%, its EBITDA margin is 50.90%, and its revenue ttm is $901.76 Million , which makes it $11.83 revenue per share.

Of the last four earnings reports from CRISPR Therapeutics AG, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.68 for the next earnings report. CRISPR Therapeutics AG’s next earnings report date is 27th Oct 2021.

The consensus rating of Wall Street analysts for CRISPR Therapeutics AG is Moderate Buy (2.09), with a target price of $163.6, which is +39.52% compared to the current price. The earnings rating for CRISPR Therapeutics AG stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CRISPR Therapeutics AG has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CRISPR Therapeutics AG has a Sell technical analysis rating based on Technical Indicators (ADX : 24.51, ATR14 : 5.07, CCI20 : -142.17, Chaikin Money Flow : -0.19, MACD : -2.27, Money Flow Index : 22.63, ROC : -5.29, RSI : 41.05, STOCH (14,3) : 18.83, STOCH RSI : 0.27, UO : 33.34, Williams %R : -81.17), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CRISPR Therapeutics AG in the last 12-months were: Bradley J. Bolzon (Sold 520 292 shares of value $76 953 403 ), James R. Kasinger (Option Excercise at a value of $1 715 969), James R. Kasinger (Sold 27 500 shares of value $5 635 943 ), Lawrence Otto Klein (Option Excercise at a value of $3 041 275), Lawrence Otto Klein (Sold 125 000 shares of value $18 185 179 ), Michael J. Tomsicek (Option Excercise at a value of $443 750), Michael J. Tomsicek (Sold 25 000 shares of value $3 462 926 ), Michael Tomsicek (Option Excercise at a value of $0), Rodger Novak (Option Excercise at a value of $1 082 250), Rodger Novak (Sold 150 000 shares of value $20 004 207 ), Samarth Kulkarni (Option Excercise at a value of $474 478), Samarth Kulkarni (Sold 70 000 shares of value $10 911 896 ), Tony W. Ho (Option Excercise at a value of $398 012), Tony W. Ho (Sold 23 551 shares of value $3 514 610 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (63.64 %)
6 (60.00 %)
6 (60.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (18.18 %)
2 (20.00 %)
2 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
2 (18.18 %)
2 (20.00 %)
2 (20.00 %)
Summary RatingModerate Buy
2.09
Moderate Buy
2.20
Moderate Buy
2.20

CRISPR Therapeutics AG

CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.

CEO: Samarth Kulkarni

Telephone: +41 415613277

Address: Baarerstrasse 14, Zug 6300, , CH

Number of employees: 410

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

86%14%

Bearish Bullish

58%42%

Bearish Bullish

58%43%

News

Stocktwits